ViroVet completes series C funding
17 June 2022
Animal health company raised close to 20 million Euro since its start in 2016
LEUVEN, Belgium, June 16th, 2022 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has successfully concluded its series C financing round, bringing the total amount raised since its start close to 20 million euros. The proceeds from the series C financing will be used to generate solid clinical data with a second vaccine in swine as well as with its BVD antiviral drug in cattle.
For further reading, please go to Virovet’s website.